Iovance Biotherapeutics (IOVA) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Iovance Biotherapeutics

NasdaqGM•Healthcare•Biotechnology

$9.87+0.51(0.05%)Pre-market

Market Cap

$4.61M

P/S

0.0x

P/B

0.0x

Iovance Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States and internationally. The company offers Amtagvi, an individualized T cell therapy for solid tumor cancer and for the treatment of adult patients with previously treated advanced, or unresectable or metastatic melanomal; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic melanoma and metastatic renal cell carcinoma. It also develops lifileucel for the treatment of melanoma, cervical cancer, non-small cell lung cancer (NSCLC), endometrial cancer, and head and neck squamous cell carcinoma (HNSCC); LN-145-S1 to treat melanoma and HNSCC; LN-145 Gen 3 and core biopsy for the treatment of NSCLC; LN-145 Gen 3 to treat melanoma and HNSCC; IOV-2001 to treat chronic lymphocytic leukemia and small lymphocytic lymphoma; IOV-4001 for the treatment of melanoma and NSCLC; and IOV-3001 for use in the TIL therapy treatment regimen. The company has collaborations and licensing agreements with National Institutes of Health; the National Cancer Institute; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.

How this company scores

AverageMetricSide Score: 54/100

Strongest: Growth (20/25); weakest: Cash & Earnings Quality (8/25).

Profitability11/25

Growth20/25

Balance Sheet & Red Flags15/25

Cash & Earnings Quality8/25

Strengths

Growing revenueInterest easily coveredProfit converts from growthConsistent growth

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/S · 0.0x5y range 0.0x – 6649.5x

Currently near its 13-quarter median.

P/B · 0.0x5y range 0.0x – 5.6x

Currently above its 20-quarter median.

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

The company posted negative operating margins in recent quarters — core operations are unprofitable.

Earnings Quality

Red Flag

Free cash flow has been negative in 8 of the last 8 quarters — earnings are not translating to cash.

Price & Volume

Market Cap $4.61M

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $330.69M
Q. Revenue: $100.66M
TTM EBITDA: $-287.99M
TTM Op. Income: $-301.31M
Q. Op. Income: $-51.91M
TTM Net Income: $-289.52M
Q. Net Income: $-47.31M
EPS: $-0.11
Shares Out.: $450,189

$330.69M in TTM revenue grew 34.2% YoY, reaching $100.66M last quarter. TTM EBITDA of $-287.99M and TTM operating income of $-301.31M show growth is flowing through to the bottom line. However, net income is negative at $289.52M — growth is not yet reaching the bottom line. Across the last 8 quarters, TTM revenue has risen for 7 consecutive quarters — an improving trend.

Margins

Gross, EBITDA, operating, and net margin trends

Gross Margin: 56.7%
EBITDA Margin: -47.8%
Op. Margin: -51.6%
Net Margin: -47.0%

Op. margin of -51.6% is up 135.4% YoY — cost efficiency is improving. Net margin at -47.0% and gross margin of 56.7% show how much of each revenue dollar survives to profit. Over the past year, operating margin is up 72% — an improving trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: N/A
P/S Ratio: 0.0x
P/B Ratio: 0.0x

P/S of 0.0x and P/B of 0.0x. P/S is low relative to typical market levels.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $915.53M
Cash: $110.77M
Long-Term Debt: N/A
Book Value: $736.04M
D/E Ratio: N/A
Debt/EBITDA: N/A

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $-60.84M
TTM Free Cash Flow: $-296.39M
FCF Margin: -89.6%
FCF / Net Income: 1.0

TTM FCF of $-296.39M on $-60.84M in operating cash flow. The FCF / Net Income ratio of 1.0x means free cash flow covers net income — earnings are backed by cash. Across the last 8 quarters, free cash flow has risen for 3 consecutive quarters — an improving trend.